Release details

2016-01-07 15:52 CET
  • Print
  • Share Share
en fr

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

Regulatory Press Release
Montrouge, France, January 6, 2016

DBV Technologies Presents its

Half-year Statement of the Liquidity Contract

As per the liquidity contract granted by DBV Technologies to NATIXIS, the following assets appeared on the liquidity account as at December 31st, 2015:

  • 3,898  DBV Technologies shares
  • EUR  1,383,821

At the last half-year DBV Technologies liquidity contract statement as at June 30th, 2015, the following resources were listed in the liquidity account:

  • 4,204 DBV Technologies shares
  • EUR 1,376,815.36

Under the terms of the liquidity contract, pursuant to Article 12, it is recalled that the following resources have been added as of December 15, 2014:

  • EUR 600,000

It is specified that at the implementation of the contract the following resources were listed in the liquidity account:

  • 0 DBV Technologies share
  • EUR 300,000.00

About DBV Technologies
DBV Technologies created the Viaskin® patch, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin while avoiding compound transfer to the blood. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergy patients, for which there are currently no approved treatments. DBV's food allergy programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis and exploring potential applications of its platform in vaccines and for the treatment selected immune diseases with unmet medical needs.
DBV Technologies has global headquarters in Paris, France and New York, NY, USA. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

HUG#1977436